We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Stand-Alone COVID-19 Rapid POC Antigen Test Delivers Results in 10 Minutes Without Separate Analyzer

By LabMedica International staff writers
Posted on 11 Nov 2020
Print article
Image: CareStart COVID-19 Antigen Rapid Point-of-Care test kit (Photo courtesy of AccessBio)
Image: CareStart COVID-19 Antigen Rapid Point-of-Care test kit (Photo courtesy of AccessBio)
A new minimally-invasive, stand-alone COVID-19 POC antigen test delivers rapid results in 10 minutes without the need for a separate analyzer.

The CareStart COVID-19 Antigen Rapid Point-of-Care (POC) test kit developed and manufactured by AccessBio (Somerset, NJ, USA) allows for rapid, effective screening of COVID-19 infection on a large scale with high sensitivity and 100% specificity. The test is available for immediate purchase by qualified healthcare providers from iRemedy Healthcare Companies, Inc. (Stuart, FL, USA) on www.iremedy.com

The CareStart COVID-19 Antigen Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare providers. Each CareStart kit contains 20 test devices, 20 assay buffers, 20 extraction vials and caps, 20 specimen collection swabs, one positive and one negative control swab and detailed simple use instructions. The stand-alone test has been authorized by the Federal Drug Administration under an Emergency Use Authorization for use by authorized laboratories and at the point-of-care by medical professionals. No separate analyzer equipment is necessary to ascertain results.

“With the second wave of COVID-19 infections underway, it is even more important that healthcare providers have the means to quickly and accurately test and confirm patients who may have contracted the coronavirus,” said Tony Paquin, co-founder and CEO of iRemedy. “Negative test confirmations are just as important, particularly for those essential workers who come into direct contact with the public through their workplaces. iRemedy is very pleased to be offering a rapid point-of-care tool that will empower healthcare providers to perform COVID-19 tests at the point-of-care without the need for specialized materials, equipment, personnel and transportation to a centralized laboratory. As a result, these tests should contribute to improving the containment of COVID-19 spread through faster, more efficient detection and subsequent isolation, when necessary.”

Related Links:
The iRemedy Healthcare Companies, Inc.

Print article


Molecular Diagnostics

view channel
Image: Schematic representation of Chiari malformation type 1; it involves the lower part of the cerebellum known as tonsils, but not the brain stem (Photo courtesy of Healthline).

Common Brain Malformation Traced to Its Genetic Roots

About one in 100 children has a common brain disorder called Chiari 1 malformation, but most of the time such children grow up normally and no one suspects a problem. However about one in 10 of those children,... Read more


view channel
Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.